Development of a supercritical CO2 extract from Mahonia Aquifolium for use in treatment of psoriasis and eczema

开发用于治疗牛皮癣和湿疹的十大功劳超临界二氧化碳提取物

• 批准号: 486383-2015
• 负责人: Kelly, Carly
• 金额: $ 1.82万
• 依托单位: Loyalist College of Applied Arts and Technology
• 依托单位国家: 加拿大
• 项目类别: Applied Research and Development Grants - Level 1
• 财政年份: 2015
• 资助国家: 加拿大
• 起止时间: 2015-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=585560
• 关键词: Development; supercritical; CO2; extract; Mahonia

The Canadian Bioceutical Corporation (BCC) is an Ontario corporation that develops and markets unique specialty nutraceutical and bioceutical products for the treatment and prevention of common ailments where present pharmaceutical treatments and over-the-counter products fail to meet the needs of patients. BCC is striving to become the most successful and innovative bioceutical company in Canada, providing clients with the highest quality and most efficacious natural products. This project will focus on 1 of BCCs current 5 product lines called Reliéva. Reliéva is an anti-inflammatory skin treatment cream with clinically proven effectiveness in psoriasis, atopic dermatitis, and dry and problematic skin. With psoriasis affecting 1 million Canadians and eczema affecting 17% of Canadians at some time in their life (Canadian Dermatology Association, 2015), Reliéva will add a Health Canada regulated natural product line that currently has minimal competitors on the market. Reliéva contains highly concentrated extracts from the Mahonia Aquifolium shrub, which contains significant levels of alkaloid, berberine. BCC has patented an extraction process, increasing the concentration of the beneficial alkaloids by 75 times, however the process is very lengthy. It is necessary for the Canadian Bioceutical Corporation to develop a more efficient extraction process in order to meet the product demand and commercialize Reliéva. This project will seek to determine the effectiveness of supercritical CO2 extraction to generate a more efficient method for the extraction of isoquinoline alkaloids from Mahonia aquifolium. The use of supercritical fluid extraction (SFE) has increased dramatically for use on natural products as a result of non-toxic, non-flammable, odourless and tasteless properties and low cost. The proposed innovation presents an opportunity to develop a higher quality product with less solvent residue using a green technology, which in turn may be transferred to other product lines for the company. The Canadian Bioceutical Corporation will benefit greatly from this project with the development of a higher quality product, generated more efficiently and at a lower cost, all while using a safer and more environmentally responsible technology. Upon successful completion of this project, BCC will be able to begin expedited production of Reliéva, allowing them to begin signing contracts with distributors locally, nationally and internationally.

加拿大生物制药公司（BCC）是安大略省的一家公司，开发和销售独特的专业营养和生物制药产品，用于治疗和预防常见疾病，目前的药物治疗和非处方产品无法满足患者的需求。BCC正努力成为加拿大最成功、最具创新精神的生物制药公司，为客户提供最优质、最有效的天然产品。该项目将重点关注bcc目前5条产品线中的1条，称为relisamuva。relisamuva是一种抗炎皮肤治疗霜，临床证明对牛皮癣，特应性皮炎，干燥和有问题的皮肤有效。由于牛皮癣影响了100万加拿大人，湿疹影响了17%的加拿大人（加拿大皮肤病协会，2015年），reli<e:1>将增加加拿大卫生部监管的天然产品线，目前市场上的竞争对手很少。reliva含有高度浓缩的Mahonia Aquifolium灌木提取物，其中含有大量的生物碱，小檗碱。BCC已经获得了提取工艺的专利，将有益生物碱的浓度提高了75倍，但是这个过程非常漫长。加拿大生物制药公司有必要开发一种更有效的提取工艺，以满足产品需求并使relisamuva商业化。本项目将试图确定超临界CO2萃取的有效性，以产生一种更有效的方法来提取Mahonia aquifolium中的异喹啉生物碱。超临界流体萃取（SFE）由于其无毒、不易燃、无臭、无味和低成本的特性，在天然产品上的应用急剧增加。提出的创新提供了使用绿色技术开发溶剂残留较少的高质量产品的机会，这反过来又可以转移到公司的其他产品线。加拿大生物制药公司将从该项目中受益匪浅，因为它将开发出质量更高、生产效率更高、成本更低的产品，同时使用更安全、更环保的技术。在该项目成功完成后，BCC将能够开始加速relisamuva的生产，使他们能够开始与当地，全国和国际分销商签订合同。